Role of tumor necrosis factor-alpha in rheumatoid arthritis: A review

APLAR Journal of Rheumatology

Volumn 10, Issue 4, 2007, Pages 270-274

  Vasanthi, Pallinti ^a   Nalini, Ganesan ^a   Rajasekhar, G ^a  

^a SRI RAMACHANDRA UNIVERSITY   (India)

Author keywords

Adalimumab; Etanercept; Infliximab; Receptor; TNF

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; METHOTREXATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

CHRONIC ARTHRITIS; COMBINATION CHEMOTHERAPY; COUGHING; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; GENETIC PREDISPOSITION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOPATHOGENESIS; INFECTION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; MONOTHERAPY; NAUSEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; PRURITUS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SINUSITIS; SPONDYLOARTHROPATHY; SYNOVIAL FLUID LEVEL; UPPER RESPIRATORY TRACT INFECTION;

EID: 36749081629     PISSN: 02190494     EISSN: 14798077     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2007.00305.x     Document Type: Review

References (40)

1. Grell M, Scheurich P (2001) Tumor Necrosis Factors. Encyclopedia of Life Sciences. Nature Publishing Group, Chennai.
2. Choy EHS, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. NEJM 344, 907-16.
3. Butler DM, Maini RN, Feldmann M, Brennan FM (1995) Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: Comparison of monoclonal anti TNF-α antibody with interleukin-1 receptor antagonist. Eur Cytokine Netw 6, 225-30.
4. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M (1991) Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-α. Eur J Immunol 21, 2575-9.
5. Chin JE, Winterrowd GE, Krzesicki RF, Sanders ME (1990) Role of cytokines in inflammatory synovitis: The coordinate regulation of intercellular adhesion molecule 1 and HLA class I and class II antigens in rheumatoid synovial fibroblasts. Arthritis Rheum 33, 1776-86.
6. Tilders FJ, DeRijk RH, Van Dam AM, Vincent VA, Schotanus K, Persoons JH (1994) Activation of the hypothalamus-pituitary-adrenal axis by bacterial endotoxins: Routes and intermediate signals. Psuedoneuroendocrinology 19, 209-32.
7. Bazzoni F, Beutler B (1996) The Tumor Necrosis Factor Ligand and Receptor familers. Seminars in Medicine of the Both Israel Hospital 344, 1717-25.
8. Kavanaugh AF, Schulze-Koops H, Davis LS, Lipsky PE (1997) Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum 40, 849-53.
9. Mahajan A, Sharma R, Singh JB (2006) Biological therapy in rheumatoid arthritis: Current Status. Ind J Rheumatol 1, 13-9.
10. Spector TD (1990) Rheumatoid arthritis. In: Hochberg M (ed.) Epidemiology of Rheumatic Diseases. Sauders, Philadelphia, PA.
11. Del Puente A, Knowler WC, Pettitt DJ, Bennett P (1981) High incidence and prevalence of rheumatoid arthritis in Pima Indians. Am J Epidemiol 129, 1170-8.
12. Kaipiainen-Seppanen O, Aho K, Nikkarinen M (2001) Regional differences in the incidence of rheumatoid arthritis in Finland in 1995. Ann Rheum Dis 60, 128-32.
13. Halliwell B (1995) Oxygen radicals, nitric oxide and human inflammatory joint disease. Ann Rheum Dis 54, 505-10.
14. Nalini G, Hariprasad C, Chandrasekaran AN, Gowri C, Poonguzhali K (1997) The antioxidant status in rheumatoid arthritis. J Clin Biochem Nutr 23, 69-75.
15. Pallinti V, Nalini G, Hariprasad C, Rajasekhar G, Meera S (2004) Plasma lipophilic antioxidant and pro-oxidant levels in rheumatoid arthritis. J Indian Rheumatol Assoc 12, 40-2.
16. Deon D, Ahmed S, Tai K, et al. (2001) Cross-Talk between IL-1 and IL-6 signaling pathways in Rheumatoid Arthritis synovial fibroblasts. J Immunol 167, 5395-403.
17. Verschueren PC, Markusse H, Smeets TJM, Kraan MC, Breedveld FC, Tak PP (1999) Reduced cellularity and expression of adhesion molecules and cytokines after treatment with soluble human recombinant TNF receptor (P75) in RA patients. Arthritis Rheum 42, S197.
18. Moots RJ (2005) Biologics - Evolution and Revolution in the management of arthritis. J Indian Rheumatol Assoc 13, 92-7.
19. Elliott MJ, Maini RN, Feldmann M, et al. (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36, 1681-90.
20. Maini R, St Clair EW, Breedveld F, et al. (1999) Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomized phase III trial. ATTRACT Study Group. Lancet 354, 1932-9.
21. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 48, 35-45.
22. den Broeder A, van de Putte L, Rau R, et al. (2002) A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 29, 2288-98.
23. Moreland LW, Schiff MH, Baumgartner SW, et al. (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130, 478-86.
24. Murray KM, Dahl SL (1997) Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR: Fc) in rheumatoid arthritis. Ann Pharmacother 311, 1335-8.
25. Genovese MC, Bathon JM, Martin RW, et al. (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum Dis 61, 793-8.
26. Zhang F-C, Hou Y, Huang F, et al. (2006) Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant Methotrexate. A preliminary study from china. APLAR J Rheumatol 9, 127-30.
27. Hur J-W, Choi C-B, Bae S-C (2006) Clinical experience with tumor necrosis factor blockers in Korean rheumatoid arthritis patients. APLAR J Rheumatol 9, 146-9.
28. Navarra SV, Raso A-A, Lichauco JJ, Tan PP (2006) Clinical experience with infliximab among Filipino patients with rheumatic disease. APLAR J Rheumatol 9, 150-6.
29. Wei JC-C, Lan J-L, Chen D-Y, Chou C-T, Chou M-C, Tsay GJ (2006) Experience of antitumor necrosis factor -α therapies in Taiwan. APLAR J Rheumatol 9, 161-4.
30. Nash P (2006) Anti-tumor necrosis factor therapy: The Australian experience. APLAR J Rheumatol 9, 119-26.
31. Kumar A (2006) Experience with anti-tumor necrosis factor-α therapy in India. APLAR J Rheumatol 9, 136-41.
32. Brandt J, Haibel H, Cornely D, et al. (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43, 1346-52.
33. Van den Bosch F, Kruithof E, Baeten D, DeKeyser F, Mielants H, Veys EM (2000) Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor (infliximab) in spondyloarthropathy: An open pilot study. Ann Rheum Dis 59, 428-33.
34. Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R (2001) Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 28, 1605-14.
35. Collantes Estevez E (2002) Treatment of refractory SpA/AS with TNFα blockers: The Spanish experience. Lecture presented at International Workshop on New Treatment Strategies in AS; 18-9 Jan 2002; Berlin, Germany.
36. Braun J, Brandt J, Listing J, et al. (2002) Treatment of active ankylosing spondylitis with infliximab - a double-blind, placebo-controlled multicenter trial. Lancet 359, 1187-93.
37. Van den Bosch F, Kruithof E, Baeten D, et al. (2002) Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 46, 755-6.
38. Field M (2001) Tumor necrosis factor polymorphisms in rheumatic diseases. Q J Med 94, 237-46.
39. Kang CP, Lee KW, Yoo DH, Kang C, Bae SC (2005) The influence of a polymorphism at position -857 of the tumour necrosis factor α gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology 44, 547-52.
40. Vasanthi P, Nalini G, Rajasekhar G, Sivasankaran V (2007) Role of TNF-α in rheumatoid arthritis - a review. Abstract. International conference and workshop on genetics: The basis and diagnosis of genetic disorders, February 1st-4th 2007, Sri Ramachandra University, Chennai.